Cenicriviroc Mesylate is primarily used in the treatment of inflammatory and fibrotic diseases, particularly those affecting the liver. It is a dual antagonist of CCR2 and CCR5 chemokine receptors, which play a significant role in the recruitment of immune cells involved in inflammation and fibrosis. This makes it a promising therapeutic agent for conditions like non-alcoholic steatohepatitis (NASH), where inflammation and fibrosis are key pathological features. By inhibiting these receptors, it helps reduce the progression of liver damage and fibrosis, offering potential benefits in managing chronic liver diseases. Additionally, its mechanism of action is being explored in other inflammatory conditions and HIV, where CCR5 is a co-receptor for viral entry.